Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-9545 + palbociclib versus anastrozole + palbociclib in neoadjuvant ER-positive/HER2-negative early breast cancer
2020-001007-16Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer and Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-) comparing GDC-9545 plus palbociclib with Anastrozole plus palbociclib (2 arms). Primary endpoint: Central assessment of changes in Ki67 scores from baseline to Week 2. Started Sep 2020; status: completed.
02
Drugs
giredestrantanastrozolepalbociclib
03
Conditions
breast cancerEstrogen receptor-positive HER2-negative breast cancer (ER+/HER2-)
Beyond the preview
Go deeper on 2020-001007-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001007-16.